Ftse Mib
33.770,82
1,86%
DAX
18.353,73
0,66%
S&P 500
5.471,75
0,21%
NASDAQ
17.732,60
0,00%
Bitcoin
62.714,73
0,19%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Cullinan Therapeutics Inc (CGEM) Cullinan Therapeutics Inc (CGEM) Notizie

CGEM

Cullinan Therapeutics (CGEM)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CGEM
DataOraFonteTitoloSimboloCompagnia
05/06/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CGEMCullinan Therapeutics Inc
04/06/202423:06Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:CGEMCullinan Therapeutics Inc
03/06/202414:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CGEMCullinan Therapeutics Inc
01/06/202413:00GlobeNewswire Inc.Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of ZipalertinibNASDAQ:CGEMCullinan Therapeutics Inc
24/05/202414:00GlobeNewswire Inc.Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation SummitNASDAQ:CGEMCullinan Therapeutics Inc
23/05/202423:04GlobeNewswire Inc.Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024NASDAQ:CGEMCullinan Therapeutics Inc
16/05/202422:10Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CGEMCullinan Therapeutics Inc
16/05/202413:30Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:CGEMCullinan Therapeutics Inc
16/05/202412:42Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CGEMCullinan Therapeutics Inc
16/05/202412:40Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CGEMCullinan Therapeutics Inc
15/05/202422:05GlobeNewswire Inc.Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsNASDAQ:CGEMCullinan Therapeutics Inc
09/05/202401:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
06/05/202422:32Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
29/04/202413:00GlobeNewswire Inc.Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial OfficerNASDAQ:CGEMCullinan Therapeutics Inc
24/04/202416:09GlobeNewswire Inc.Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024NASDAQ:CGEMCullinan Therapeutics Inc
16/04/202413:00GlobeNewswire Inc.Cullinan Therapeutics Announces Strategic Expansion into Autoimmune DiseasesNASDAQ:CGEMCullinan Therapeutics Inc
16/04/202412:59GlobeNewswire Inc.Cullinan Therapeutics Announces Oversubscribed $280 million Private PlacementNASDAQ:CGEMCullinan Therapeutics Inc
14/03/202412:00GlobeNewswire Inc.Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:CGEMCullinan Therapeutics Inc
01/03/202413:00GlobeNewswire Inc.Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple MyelomaNASDAQ:CGEMCullinan Therapeutics Inc
27/02/202414:00GlobeNewswire Inc.Cullinan Oncology to Participate in Upcoming Investor ConferencesNASDAQ:CGEMCullinan Therapeutics Inc
15/02/202403:01Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CGEMCullinan Therapeutics Inc
08/01/202422:15Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:CGEMCullinan Therapeutics Inc
18/12/202322:53GlobeNewswire Inc.Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:CGEMCullinan Therapeutics Inc
14/12/202322:30GlobeNewswire Inc.Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 CytokinesNASDAQ:CGEMCullinan Therapeutics Inc
08/11/202313:22Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CGEMCullinan Therapeutics Inc
08/11/202313:00GlobeNewswire Inc.Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsNASDAQ:CGEMCullinan Therapeutics Inc
03/11/202317:01GlobeNewswire Inc.Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023NASDAQ:CGEMCullinan Therapeutics Inc
10/08/202313:00GlobeNewswire Inc.Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial ResultsNASDAQ:CGEMCullinan Therapeutics Inc
09/08/202313:00GlobeNewswire Inc.Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin LymphomaNASDAQ:CGEMCullinan Therapeutics Inc
03/08/202322:15PR Newswire (US)REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion MutationsNASDAQ:CGEMCullinan Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CGEM

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
BPE
Bper Banca
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
ENEL
Enel
BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
STMMI
ST Microelectronics
BIT
SPM
Saipem
BIT
RACE
Ferrari NV
BIT
PRY
Prysmian
BIT
CPR
Davide Campari
BIT
BAMI
Banco BPM
BIT
FCTAAW
Fincantieri
BIT
LDO
Leonardo
BIT
TEN
Tenaris
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network